Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9683986
APP PUB NO 20140329261A1
SERIAL NO

14364582

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)75016 PARIS
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)75013 PARIS
HOSPICES CIVILS DE LYON69229 LYON CEDEX 02
UNIVERSITE CLAUDE BERNARD LYON 143 BOULEVARD DU 11 NOVEMBRE 1918 VILLEURBANNE 69100
CENTRE LEON BERARD69008 LYON

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Coste-Invernizzi, Isabelle Chazey d'Azergues, FR 8 18
Kfoury, Alain Lyons, FR 1 0
Lebecque, Serge Civrieux d'Azergues, FR 9 33
Renno, Toufic Civrieux d'Azergues, FR 9 18

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 20, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 20, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00